XTNT (Xtant Medical Holdings) ROCE %: -15.90% (As of Mar. 2026)

What is Xtant Medical Holdings ROCE %?

Xtant Medical Holdings XTNT -1.16% 31 ROCE % is -15.90% as of Mar. 2026. GuruFocus rates XTNT with a GF Score™ of 31/100 and a GF Value™ of $0.62 (Possible Value Trap). The stock has 4 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Xtant Medical Holdings's annualized ROCE % for the quarter that ended in Mar. 2026 was -15.90%.

Xtant Medical Holdings (AMEX:XTNT) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Xtant Medical Holdings ROCE % Related Terms

Xtant Medical Holdings ROCE % Historical Data

* Premium members only.

The historical data trend for Xtant Medical Holdings's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Xtant Medical Holdings ROCE % Chart

Xtant Medical Holdings Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

ROCE %

Get a 7-Day Free Trial

-12.97

-15.17

3.32

-17.95

16.43

Xtant Medical Holdings Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
ROCE %	Get a 7-Day Free Trial															6.56	27.65	13.75	13.68	-15.90

31GF Score

Xtant Medical Holdings Inc XTNT

ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Xtant Medical Holdings ROCE % Calculation

Xtant Medical Holdings's annualized ROCE % for the fiscal year that ended in Dec. 2025 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2025 )		(A: Dec. 2024 )		(A: Dec. 2025 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2025 )		(A: Dec. 2024 )		(A: Dec. 2025 )
	=	10.672	/	( ( (93.837 - 28.581)	+	(94.145 - 29.484) )	/ 2 )
	=	10.672	/	( (65.256	+	64.661)	/ 2 )
	=	10.672	/	64.9585
	=	16.43 %

Xtant Medical Holdings's ROCE % of for the quarter that ended in Mar. 2026 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Mar. 2026 )		(Q: Dec. 2025 )		(Q: Mar. 2026 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Mar. 2026 )		(Q: Dec. 2025 )		(Q: Mar. 2026 )
	=	-9.852	/	( ( (94.145 - 29.484)	+	(78 - 18.773) )	/ 2 )
	=	-9.852	/	( ( 64.661	+	59.227 )	/ 2 )
	=	-9.852	/	61.944
	=	-15.90 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

Frequently Asked Questions Learn more about ROCE % →

What does a ROCE % of -15.90% mean?

Xtant Medical Holdings (XTNT) has a ROCE % of -15.90% as of Mar. 2026.

Is Xtant Medical Holdings' ROCE % too high?

Xtant Medical Holdings' current ROCE % is -15.90%. Overall, Xtant Medical Holdings has a GF Score™ of 31/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.

How does Xtant Medical Holdings' ROCE % compare to MDAI and QTI?

Xtant Medical Holdings' ROCE % of -15.90% can be compared against companies in the Medical Devices & Instruments industry. The industry median ROCE % is 2.23. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good ROCE % for a Medical Devices & Instruments company?

The median ROCE % among Medical Devices & Instruments companies is 2.23, based on 814 companies in the industry. Companies in the top quartile (top 25%) have a ROCE % significantly above this median, while those in the bottom quartile fall well below. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high ROCE % mean?

A high ROCE % can signal that a stock is expensive relative to its fundamentals. For the Medical Devices & Instruments industry, the median ROCE % is 2.23 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Xtant Medical Holdings's current ROCE % is -15.90%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Xtant Medical Holdings stock overvalued right now?

Based on GuruFocus' analysis, Xtant Medical Holdings (XTNT) is currently considered Possible Value Trap. The stock's GF Value™ is $0.62, compared to a current price of $0.43 — trading 31.5% below its estimated fair value. The current ROCE % is -15.90%. Xtant Medical Holdings' overall GF Score™ is 31/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is ROCE % calculated?

ROCE % is calculated from a company's financial statements. For Xtant Medical Holdings (XTNT), the current ROCE % is -15.90% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Xtant Medical Holdings (XTNT) Overvalued in 2026?

Based on GuruFocus' analysis, Xtant Medical Holdings stock appears to be undervalued. The current stock price of $0.43 is trading 31.5% below its estimated GF Value™ of $0.62. GuruFocus considers Xtant Medical Holdings to be Possible Value Trap.

Key valuation signals for XTNT:

ROCE %: -15.90%
GF Value™: $0.62 vs. price of $0.43 (31.5% below fair value)
GF Score™: 31/100 with 4 warning signs

No single metric tells the full story. See the XTNT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Xtant Medical Holdings Business Description

Industry Healthcare Medical Devices & Instruments

Comparable Companies MDAI QTI POSC LUNG LNSR RTGN COCH ELUT SRTS ECOR ABT SYK MDT BSX EW XTER:SHL DXCM GEHC SZSE:300760 XAMS:PHIA

Address 664 Cruiser Lane, Belgrade, MT, USA, 59714

Website http://www.xtantmedical.com

Xtant Medical Holdings Inc is a medical technology company focused on the design, development, and commercialization of a comprehensive portfolio of orthobiologics and spinal implant systems to facilitate spinal fusion in complex spine, deformity and degenerative procedures. Its products are used by orthopedic spine surgeons and neurosurgeons to treat a variety of spinal disorders in the cervical, thoracolumbar, and interbody spine. The company's biomaterial products include OsteoSponge, OsteoSponge SC, OsteoSelect Plus DBM putty, OsteoWrap, and the line of 3Demin products, as well as other allografts. It generates a majority of its revenue from the U.S.

31GF Score

Get the complete analysis for XTNT

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.43

Price

$0.62

GF Value

View XTNT Analysis

See ROCE % data for all stocks →